Virbac SA (VIRP.PA) — Quality & forensics
As of 2026-10-12 — refreshed nightly. Closelooknet readings from an investment research diary, not ratings or advice.
The Closelooknet module scores
- Valuation 61
- Quality 51
- Growth 34
- Balance sheet 64
- Cash quality 48
- Capital allocation 34
- Momentum 35
Scores are computed nightly across the coverage universe and read relative to it — the methodology lives in the company-scoring explainer.
Financial forensics — the academic screens
Sits in the safe zone (above 2.99). The Z-Score estimates financial-distress risk from five balance-sheet and earnings ratios.
Nine binary fundamental-strength checks across profitability, leverage and operating efficiency.
Screens reported earnings for statistical manipulation patterns — below the −1.78 manipulation-risk threshold. A screen, not an accusation.
Continue: the VIRP.PA chart & overview
FAQ · from the current data · as of 2026-10-12
Quick answers
What is Virbac SA's Closelooknet quality reading?
The composite reads 47/100 across 7 modules, as of 2026-10-12: valuation 61, quality 51, growth 34, balance sheet 64, cash quality 48, capital allocation 34, momentum 35. Closelooknet scores are research diary readings, not ratings or investment advice.
What is Virbac SA's Altman Z-Score?
3.44, which sits in the safe zone (above 2.99) as of 2026-10-12. The Altman Z-Score estimates financial distress risk from five balance-sheet and earnings ratios.
What is Virbac SA's Piotroski F-Score?
7 of 9, as of 2026-10-12. The F-Score counts nine binary fundamental-strength signals across profitability, leverage and operating efficiency.
What does Virbac SA's Beneish M-Score indicate?
-2.04 — below the −1.78 manipulation-risk threshold, as of 2026-10-12. The M-Score screens reported earnings for statistical manipulation patterns; it is a screen, not an accusation.
Related in the Closelooknet universe
then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.
- LLY Eli Lilly and Companyindustry
- ORNAV.HE Orion Oyj Aindustry
- ORNBV.HE Orion Oyj Bindustry
- SAN.PA Sanofi SAindustry
- NVO Novo Nordisk A/Sindustry
- GSK GlaxoSmithKline PLC ADRindustry
- ABBV AbbVie Incindustry
- BIIB Biogen Incindustry
- GILD Gilead Sciences Incindustry
- PFE Pfizer Incindustry
- MRK Merck & Company Incindustry
- AMGN Amgen Incindustry
- OGN Organon & Coindustry
- JNJ Johnson & Johnsonindustry
- SNY Sanofi ADRindustry
- BMY Bristol-Myers Squibb Companyindustry
- AZN AstraZeneca PLCindustry
- EL.PA EssilorLuxottica S. A.sector
- ABVX.PA Abivax SAsector
- NANO.PA Nanobiotix S.Asector